This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Dermatologic Disorders, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The phase 1 trials of finasteride (Propecia/Proscar; Merck) have shown that finasteride at 1 mg (Propecia) as well as finasteride at 5 mg (Proscar) blocks 5- reductase.

The genetic, biochemical, epidemiological, experimental, and clinical reasons for my warning^1-2 3 years ago that use of finasteride promotes prostate cancer have been confirmed by the findings of a finasteride chemoprevention trial (Prostate Cancer Prevention Trial [PCPT]) involving 18 882 men followed up for 7 years. The trial was stopped after 9060 men underwent biopsy during the trial or at the end of 7 years.

It was found that "Finasteride prevents or delays the appearance of prostate cancer" by 24.6% (finasteride, 803/4368 [18.4%]; placebo, 1147/4692 [24.4%]) but "increased the risk of high-grade prostate cancer (Grade 7, 8, 9, 10)" by 67% (finasteride, 280/757 [37%]; placebo, 237/1068 [22.2%] [P<.001]) in men diagnosed as having prostate cancer.³

Patrick Walsh, MD, stated in his critique . . . [Full Text of this Article]

W. Reid Pitts, Jr, MD

Correspondence: Dr Pitts, 115 E 61st St, New York, NY 10021.